Silver sulfadiazine 10 mg/g Cream, 50 g
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Sulfonamide Antibacterial class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections of second- and third-degree burns. It kills a wide variety of bacteria. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Read the full MedlinePlus article ↗- Silver sulfadiazine cream is applied to second- and third-degree burn wounds to help prevent and treat serious infection. It's not a standalone treatment — your care team uses it a...
- After the wound is cleaned and any dead tissue is removed, the cream is spread in a thin layer — about 1/16 of an inch — directly over the burn area. It's applied once or twice a d...
- A temporary dip in white blood cells, especially a type called neutrophils, is actually one of the more commonly reported effects — it happens in roughly 1 in 5 patients. The good...
- My white blood cell count went down — should I be worried?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Silver Sulfadiazine — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 0RE8K4LNJS
Isopropyl myristate is an oily liquid made from coconut or palm oil. It's used in medicines as an emollient and penetration enhancer to help the medicine absorb through skin or improve spreadability in topical products.
-
3 mg / 1 g
UNII A2I8C7HI9T
Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
-
UNII 4T6H12BN9U
Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
-
UNII 13A4J4NH9I
A synthetic emulsifier derived from stearic acid and polyethylene glycol. It helps mix oil and water-based ingredients together in liquid medicines and creams to create a smooth, uniform product.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII 06XEA2VD56
Sorbitan oleate is an emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together and keeps them from separating in the medicine.
-
UNII 2KR89I4H1Y
Stearyl alcohol is a waxy, fatty substance derived from natural oils or made synthetically. It acts as an emulsifier and thickener in medicines, helping mix ingredients together and give the product the right texture.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
8 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.255 | $12.76 / 50 g |
| Medicaid paysCMS SDUD · 12 mo | $0.2579 | $12.90 / 50 g |
| Medicare drug plans payPart D · Q2 2026 | $0.2091 | $10.46 / 50 g |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Silver sulfadiazine 10 mg/gthis 67877-0124-50 | Ascend | 50 g | $0.255 | AB | Availability likely | — |
| SSD Cream 10 g/1000g 43598-0210-25 | Dr | 25 g | $0.316 | AB | Availability likely | +24% |
| Silver Sulfadiazine 10 mg/g 59762-0131-00 | Mylan | 1 tube | $0.403 | AB | Availability likely | +58% |
| Silvadene 10 mg/g 61570-0131-20 | Pfizer | 1 tube | $0.433 | AB | Availability likely | +70% |
| Silvadene 10 mg/g 50090-0230-00 | A-S | 1 tube | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 50090-0607-00 | A-S | 50 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 50090-0717-00 | A-S | 50 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 50090-0763-00 | A-S | 25 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 50090-2152-00 | A-S | 400 g | — | AB | FDA listed | — |
| Ssd 10 g/1000g 50090-7447-00 | A-S | 50 g | — | AB | FDA listed | — |
| SSD Cream 10 g/1000g 60760-0962-50 | St. | 50 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 g/1000g 61919-0237-25 | DIRECT | 25 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 63187-0023-25 | Proficient | 25 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 63629-8768-01 | Bryant | 20 g | — | AB | Discontinued | — |
| Silver Sulfadiazine 10 mg/g 63629-8769-01 | Bryant | 25 g | — | AB | Discontinued | — |
| Silver Sulfadiazine 10 mg/g 63629-8770-01 | Bryant | 50 g | — | AB | Discontinued | — |
| Silver Sulfadiazine 10 mg/g 63629-8771-01 | Bryant | 50 g | — | AB | Discontinued | — |
| Silver Sulfadiazine 10 mg/g 63629-8772-01 | Bryant | 85 g | — | AB | Discontinued | — |
| Silver Sulfadiazine 10 mg/g 63629-8773-01 | Bryant | 400 g | — | AB | Discontinued | — |
| Silver Sulfadiazine 10 g/1000g 68071-2473-05 | NuCare | 50 g | — | AB | FDA listed | — |
| SSD Cream 10 g/1000g 68071-3867-05 | NuCare | 50 g | — | AB | FDA listed | — |
| Thermazene Silver Sulfadiazine 10 mg/g 68788-0600-02 | Preferred | 25 g | — | AB | FDA listed | — |
| SSD Cream 10 g/1000g 68788-8074-02 | Preferred | 25 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 g/1000g 76420-0208-25 | Asclemed | 25 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 80425-0221-01 | Advanced | 50 g | — | AB | FDA listed | — |
| Silver Sulfadiazine 10 mg/g 87063-0078-05 | Asclemed | 50 g | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 67877-0124-05 | 50 g in 1 TUBE (67877-124-05) | $0.2551 / g | $12.76 | 1985-12-23 | Active |
| 67877-0124-10 | 1000 g in 1 JAR (67877-124-10) | — | — | 1985-12-23 | Active |
| 67877-0124-20 | 20 g in 1 TUBE (67877-124-20) | $0.4027 / g | $8.05 | 1985-12-23 | Active |
| 67877-0124-25 | 25 g in 1 TUBE (67877-124-25) | $0.3159 / g | $7.90 | 1985-12-23 | Active |
| 67877-0124-40 | 400 g in 1 JAR (67877-124-40) | $0.1265 / g | $50.61 | 1985-12-23 | Active |
| 67877-0124-50 You're viewing this | 50 g in 1 JAR (67877-124-50) | $0.2551 / g | $12.76 | 1985-12-23 | Active |
| 67877-0124-85 | 85 g in 1 TUBE (67877-124-85) | $0.2622 / g | $22.28 | 1985-12-23 | Active |
Per g, this pack runs about 102% above the cheapest pack (400 g, $0.1265 vs $0.2551 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 38% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 67877-0124-50?
What is the difference between NDC 67877-0124-50 and NDC 67877-0124-20?
What NDC number is used to bill for this package of Silver sulfadiazine 10 mg/g Cream?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided ; silver sulfadiazine cream, USP 1% is then applied under sterile conditions. The burn areas should be covered with silver sulfadiazine cream, USP 1% at all times.
The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed by patient activity. Administration may be accomplished in minimal time because dressings are not required.
However, if individual patient requirements make dressings necessary, they may be used. Reapply immediately after hydrotherapy. Treatment with silver sulfadiazine cream, USP 1% should be continued until satisfactory healing has occurred or until the burn site is ready for grafting.
The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.
⛔ Contraindications ▾
CONTRAINDICATIONS Silver sulfadiazine cream, USP 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. Because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, USP 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.
⚠️ Warnings ▾
WARNINGS Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, and hemolytic anemia; dermatologic and allergic reactions, including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and exfoliative dermatitis]; gastrointestinal reactions, hepatitis and hepatocellular necrosis; CNS reactions; and toxic nephrosis.
There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction. Fungal proliferation in and below the eschar may occur.
However, the incidence of clinically reported fungal superinfection is low. The use of silver sulfadiazine cream, USP 1% in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy. 1,2,3 Leukopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy.
Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. An increased incidence has been seen in patients treated concurrently with cimetidine.
Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis. Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial-thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture.
🤰 Pregnancy ▾
PREGNANCY: TERATOGENIC EFFECTS: Pregnancy Category B. A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in silver sulfadiazine cream, USP 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine. There are, however, no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term. (See CONTRAINDICATIONS ) Nursing Mothers. It is not known whether silver sulfadiazine cream, USP 1% is excreted in human milk.
However, sulfonamides are known to be excreted in human milk and all sulfonamides derivatives are known to increase the possibility of kernicterus. Because of the possibility for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Geriatric Use.
Of the total number of subjects in clinical studies of silver sulfadiazine cream, USP 1%, seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Pediatric Use.
Safety and effectiveness in children have not been established. (See CONTRAINDICATIONS )
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below.
Sufficient data have been obtained to demonstrate that silver sulfadiazine will inhibit bacteria that are resistant to other antimicrobial agents and that the compound is superior to sulfadiazine. Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect.
Results of in Vitro Testing With Silver Sulfadiazine Cream, USP 1% Concentration of Silver Sulfadiazine Number of Sensitive Strains / Total Number of Strains Tested Genus and Species 50 µg/mL 100 µg/mL Pseudomonas aeruginosa 130/130 130/130 Xanthomonas (Pseudomonas) Maltophilia 7/7 7/7 Enterobacter species 48/50 50/50 Enterobacter cloacae 24/24 24/24 Klebsiella species 53/54 54/54 Escherichia coli 63/63 63/63 Serratia species 27/28 28/28 Proteus mirabilis 53/53 53/53 Morganella morganii 10/10 10/10 Providencia rettgeri 2/2 2/2 Proteus vulgaris 2/2 2/2 Providencia species 1/1 1/1 Citrobacter species 10/10 10/10 Acinetobacter calcoaceticus 10/11 11/11 Stahylococcus aureus 100/101 100/101 Staphylococcus epidermidis 51/51 51/51 β-Hemolytic Streptococcus 4/4 4/4 Enterococcus species 52/53 52/53 Corynebacterium diphtheriae 2/2 2/2 Clostridium perfringens 0/2 2/2 Candida albicans 43/50 50/50 Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Silver sulfadiazine cream, USP 1% - white to off-white cream NDC Number Size 67877-124-20 20g tube 67877-124-25 25g tube 67877-124-05 50g tube 67877-124-85 85g tube 67877-124-50 50g jar 67877-124-40400g jar 67877-124-101000g jar Store at room temperature. 15°-30°C (59°-86°F). Manufactured for: Ascend Laboratories, LLC Parsippany, NJ 07054 Manufactured by: Crown Laboratories, Inc.
Johnson City, TN 37604 Product Information : 1-877-272-7901 Revised: DEC 2018 P1840.05
📋 Description ▾
DESCRIPTION Silver sulfadiazine cream, USP 1% is a soft, white, water dispersible cream containing the antimicrobial agent silver sulfadiazine in micronized form for topical application. Each gram of silver sulfadiazine cream contains 10mg of micronized silver sulfadiazine. This active agent has the following structural formula: Silver sulfadiazine cream contains 1% w/w silver sulfadiazine.
The vehicle in which the active ingredient is dispersed consists of water, stearyl alcohol, white petrolatum, polyoxyl 40 stearate, propylene glycol, isopropyl myristate, and sorbitan monooleate with 0.3% methylparaben as a preservative. structure